• Benign Prostatic Hyperplasia
  • Hormone Therapy
  • Genomic Testing
  • Next-Generation Imaging
  • UTUC
  • OAB and Incontinence
  • Genitourinary Cancers
  • Kidney Cancer
  • Men's Health
  • Pediatrics
  • Female Urology
  • Sexual Dysfunction
  • Kidney Stones
  • Urologic Surgery
  • Bladder Cancer
  • Benign Conditions
  • Prostate Cancer

FDA clears laser device for BPH

Article

Trimedyne, Inc., Irvine, CA, has received FDA approval to market its VaporMAX Fiber for use with its Holmium lasers to treat BPH.

Trimedyne, Inc., Irvine, CA, has received FDA approval to market its VaporMAX Fiber for use with its Holmium lasers to treat BPH. The new side-firing laser fibers vaporize an average of 3 grams of soft tissue over 60 minutes of use. This faster vaporization rate minimizes physician and operating room time, according to the company.

The company also said that product testing has indicated that the fibers are more durable than other side-firing fibers, meaning that one device should be sufficient to treat even large prostates.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.